Facebook Pixel Code
Banner image
Adeli Lab

Research areas

Research programs in the Adeli Lab focus on the following areas:

Clinical and Translational Research Studies

CALIPER Program – Paediatric Reference Standards for Biomarkers of Health & Disease

Dr. Adeli has been leading a national initiative in collaboration with other paediatric health centres across Canada to establish a comprehensive database of pediatric reference standards for laboratory biomarkers of paediatric disease. The new database will improve the clinical assessment, diagnosis, and monitoring of children and adolescents presenting with various medical concerns. The database has been largely completed and is available on the CALIPER project website via a web application as well as via a Mobile Application available on iTunes and Google Play. 

The CALIPER App provides easy access to comprehensive and up-to-date paediatric reference standards for over 170 tests routinely performed in children and adolescents. It was developed for paediatricians, family physicians and other health-care professionals to facilitate interpretation of medical test results and improve the accuracy of medical decision-making in children.

In the CALIPER program, prospective and retrospective studies are also underway to investigate the influence of age, sex, ethnicity, Body Mass Index (BMI) and other factors on biomarker levels in children and adolescents. Furthermore, the impact of obesity and insulin resistance on fasting and postprandial lipid metabolism is being investigated in adolescents with obesity and different degrees of insulin resistance.

Fundamental Research Studies

Neuroendocrine Regulation of Lipid and Lipoprotein Metabolism in Obese and Diabetic States

Insulin resistant states (obesity, metabolic syndrome, and type 2 diabetes) have become a global epidemic in both children and adults and are major risk factors for atherosclerotic cardiovascular disease, largely due to lipid and lipoprotein abnormalities. The key mechanism underlying this metabolic dyslipidemia is hepatic and intestinal overproduction of atherogenic lipoproteins. The focus of our basic research program has been to understand the cellular, molecular and physiological regulation of intestinal chylomicron and hepatic liporprotein (VLDL) production in normal and insulin resistant states.

Our laboratory was first to demonstrate intestinal chylomicron overproduction in the insulin resistant hamster and the novel role of gut hormones (glucagon-like peptides (GLP)-1 and GLP-2), observations that have now been confirmed in humans. Most recently, we have discovered and reported a complex gut-brain axis (via CNS receptors) triggered following fat ingestion to modulate intestinal chylomicron production by GLP-1. Our current studies are focused on determining the neuroendocrine and molecular mechanisms that control dietary fat absorption and lead to chylomicron overproduction and diabetic dyslipidemia in insulin resistant states.